A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population
Status:
Terminated
Trial end date:
2018-01-02
Target enrollment:
Participant gender:
Summary
This is a multi-national, phase II, single arm study to explore the safety/efficacy and
potential biomarkers on sunitinib 2/1 schedule for Asian patients with advanced renal cell
carcinoma.